Is it safe to color my hair during or after chemotherapy?

 

Q: My sister had the Whipple procedure last June and is now going through chemotherapy 1 day a week. Is it safe for me to give her hair a permanent wave?

Q: Now that I have finished chemo and am taking Herceptin®, my hair is growing back. Is it safe to start coloring my hair again?

A: Because chemotherapy may cause hair loss (either partial or total), you should not perm, dye, or straighten the remaining hair during treatment. These cosmetic processes stress the hair and skin with chemicals and give off fumes that can cause nausea, eye irritation, and other problems. Cutting your hair shorter may help it look more full, instead of having a perm. Use only gentle moisturizing shampoos, conditioners, and skin creams.

After treatment, your hair and scalp are still sensitive, so continue to use gentle hair products. If you’ve lost your hair, it may regrow in a different texture and body. Wait until your hair has regrown for about 6 months to see its new condition before considering coloring, perming, or straightening it again. Talk with your doctor before using any hair processing agent. This is particularly important if you are on continuing medication.

--Bernice Crook, RN, OCN

Find out tips on looking good while going through treatment.

Latest Cancer News
Test Available for Pre-surgical Evaluation of Ovarian Mass

March 11, 2010 — For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon. The test assesses the likelihood that cancer is present; when cancer is likely, surgery may best be performed by a gynecologic oncologist.

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole

March 10, 2010 — Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported

March 10, 2010 — Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Select news items provided by Reuters Health